Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Longeveron Inc
(NQ:
LGVN
)
1.610
-0.070 (-4.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Longeveron Inc
< Previous
1
2
3
4
Next >
BioMedNewsBreaks – H.C. Wainwright & Co. Reiterates ‘Buy’ Rating, $6 PT on Longeveron (NASDAQ: LGVN)
February 06, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Dietician Tips for Boosting Muscle Mass, Living Longer
January 31, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Granted US Patent Allowance for Key Technology Behind Lead Investigation Product
January 29, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Scientists Discover Alzheimer’s Can Be Categorized into Five Subtypes
January 18, 2024
Via
Investor Brand Network
Five Significant Strides Made in Alzheimer’s Research in 2023
January 05, 2024
Via
Investor Brand Network
Studies Suggest Fasting Could Tone Down Alzheimer’s Signs
December 22, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Enters Definitive Agreement for $2.36M Registered Direct Offering
December 21, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Reports Additional Positive Clinical Data, Imaging Biomarker Results in Phase 2a Lomecel-B(TM) Trial
December 20, 2023
Via
Investor Brand Network
Smart Trackers Could Detect Aging-Related Complications in Seniors
December 12, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Eyes ‘Encouraging’ Results from CLEAR MIND Trial
December 01, 2023
Via
Investor Brand Network
Hidden Belly Fat Could Be a Precursor of Alzheimer’s Onset Years Later
November 30, 2023
Via
Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) Encouraged by Positive Results from Phase 2a Trial in Patients with Mild AD; Explores Paths Forward for the Development of Lomecel-B(TM)
November 21, 2023
Via
Investor Brand Network
Study Links Cat Parasite to Accelerated Frailty in Aging People
November 16, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Featured in Bell2Bell Podcast
November 14, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Study Survival Data Reported at AHA’s 2023 Scientific Sessions
November 13, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Announces 2023 Results, Provides Corporate Update
November 10, 2023
Via
Investor Brand Network
Sex Hormones Could Influence Alzheimer’s Development, Researchers Say
November 06, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Plans to Release Q3 2023 Financial Report, Host Corporate Update Call
November 03, 2023
Via
Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial
October 30, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Top-Line Results from Phase 2a Trial Spotlighted in Latest NNA Release
October 24, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Closes on $4M Registered Direct Offering
October 16, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Enters into $4M Registered Direct Offering
October 12, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Reports Top-Line Results for Phase 2a Lomecel-B Clinical Trial
October 05, 2023
Via
Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) Eyeing Global HLHS, in addition to Alzheimer’s Disease, and Aging-Related Frailty Treatment Markets with Lomecel-B(TM), its Lead Investigational Product
September 27, 2023
Via
Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) to Discuss Its Cellular Therapy Programs, Clinical Trial Progress at the 25th Annual H.C. Wainwright Global Investment Conference
September 14, 2023
Via
Investor Brand Network
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
September 12, 2023
By David Willey, Benzinga
Via
TheNewswire.com
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) CEO Releases Stockholder Letter
September 11, 2023
Via
Investor Brand Network
Longeveron Inc. (NASDAQ: LGVN) Is ‘One to Watch’
September 08, 2023
Via
Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces ELPIS 1 Trial Data Accepted for AHA Presentation, IBN Partnership
September 07, 2023
Via
Investor Brand Network
Upcoming Phase 2 Data Expected For Longeveron’s (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer’s Sector – What To Look For
September 07, 2023
By David Willey, Benzinga
Via
TheNewswire.com
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.